<DOC> 
<DOCNO>1090728_business_story_11290906.utf8</DOCNO> 
<TEXT> 
         
The Telegraph - Calcutta (Kolkata) | Business | Sanofi buys Shantha Bio
                                                                                                               Sanofi buys Shantha Bio
          OUR SPECIAL CORRESPONDENT                          Shot in the arm                                  
	Mumbai, July 27: French drug maker Sanofi-aventis will acquire Hyderabad-based Shantha Biotechnics for 550 million euros ($781 million).        
	Sanofi has pipped GlaxoSmithKline to pick up an 80 per cent stake in the Indian vaccine maker.        
	The deal, which is set to close before the end of the third quarter, shows the growing importance of Asia and other emerging economies in the global map.        
	Sanofi has struck three deals in emerging markets. For the latest transaction, it acquired the French subsidiary of Merieux Alliance  ShanH  which owns 80 per cent in Shantha Biotechnics.         
	Merieux  the eponymous company of billionaire Alain Mrieux  had acquired a majority stake in Shantha Biotechnics three years ago.         
	Under the terms of the agreement, Sanofi Pasteur, the vaccine division of the Sanofi group, will support Shantha in the development of affordable vaccines for the global markets.        
	Varaprasad Reddy, who founded Shantha Biotechnics in 1993, will continue to lead the company as the managing director.        
	In the current fiscal, sales of Shantha Biotechnics, which is an unlisted company, are expected to be around $90 million.         
	Christopher A. Viehbacher, CEO of Sanofi-aventis, said, Shantha provides Sanofi Pasteur with a portfolio of new vaccines under development which complement Sanofi Pasteurs current vaccines.                                                                                                                                        
</TEXT> 
</DOC>